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The long-standing quest for the devel-
opment of vaccines that confer protection
against highly mutable viruses such as
HIV, hepatitis C, and influenza has
elicited numerous structural and function-
al studies on virus-neutralizing human
antibodies. These studies have aimed at
translating the knowledge acquired on
broadly neutralizing antibodies to the
design of better immunogens for the
induction of specific and protective im-
mune responses. The last few months were
marked by several seminal articles that
investigate HIV-neutralizing human anti-
bodies. These studies have characterized
essential mechanistic details of the neu-
tralization of HIV and imply that both
exquisite specificity and degeneracy of the
specificity of antibodies may be equally
important for HIV neutralization. In this
Opinion, we highlight and further discuss
the potential of polyreactive (promiscuous)
antibodies in defense against promptly
evolving viruses. Despite having been
somewhat neglected by mainstream im-
munologists in the last 20 years, polyreac-
tive antibodies may come to light as new
weapons against HIV.
Strategies of HIV for Evading
the Immune Response
HIV infection is characterized by the
production of large amount of diverse
virus-specific antibodies; these antibodies
are, however, not capable of efficiently
controlling virus propagation [1]. This is
explained by the sophisticated immune
evasion strategies of HIV [1,2]. Members
of the Retroviridae family possess an
error-prone reverse transcriptase that in-
troduces mutations at high frequency
during reverse transcription of viral RNA
into DNA [2]. Random mutations also
affect the viral spike protein gp120, which
mediates the attachment of HIV to the
CD4 molecule on the host cells [2].
Indeed, the extraordinary diversity in the
sequence of the surface motifs in gp120
explains the escape of HIV from effective
neutralization by antibodies. The muta-
tion-driven viral evolution is so intense
that, in individual patients, versatile gp120
variants and even quasi-species of HIV are
generated [1]. Paradoxically, the pressure
exerted by the humoral immune response
shapes gp120 diversity during the course
of the infection. Another mechanism for
immune evasion by HIV, defined as
entropic masking [3], is related to the
enormous structural flexibility of unbound
gp120 [2]. Thus, gp120 displays many
functionally irrelevant structural variants,
a heterogeneity that misleads the immune
system and skews the humoral immune
response [3,4]. Lastly, HIV also takes
advantage of the immune inertness of
host-derived glycans to shield binding
epitopes on gp120 that are important for
the virus, thus physically preventing anti-
body access [3,5].
HIV-Neutralizing Antibodies
Despite the ability of HIV to escape
immune recognition, some individuals
with long-standing HIV infection do
generate broadly neutralizing antibodies;
these antibodies were found to potently
neutralize different HIV genetic variants
[1,6,7]. Scientists were encouraged to
characterize such immunoglobulins as
templates to design novel vaccines. By
using selection technologies, a number of
broadly neutralizing human antibodies
have been isolated [8]. The characteriza-
tion of their interaction with gp120 or
gp41 at the atomic level has allowed for
the mapping of the sites on the viral
surface that are sensitive to neutralization.
Thus, regions on gp120 such as the CD4-
binding site, the CD4-induced site (i.e., the
site on gp120 which is exposed upon
binding of CD4 to gp120), the co-receptor
binding site, and the membrane-proximal
external region (MPER) site on gp41 have
been identified as essential targets for
neutralizing antibodies [8]. Collectively,
these endeavors have led to the emergence
of the field of ‘‘structure-assisted rational
vaccine design’’, where structural infor-
mation is used for the development of
immunogens that elicit immune responses
targeted specifically to sites on spike
proteins that are vulnerable to neutraliza-
tion by antibodies [9]. Recently published
work [10,11] describes such innovative
strategies for the selection, from the
peripheral blood of infected patients, of
potent neutralizing antibodies to gp120
with broad clade specificity. The structural
analyses of one of these antibodies showed
that it binds to the CD4-binding site on
gp120 [11]. The binding of this antibody
mimics advantageously the interaction of
CD4 with gp120, demonstrating how
extreme optimization of antibody specific-
ity by affinity maturation and accumula-
tion of somatic mutations may result in
high HIV neutralization potency. More-
over, the work of Zhou implies that, in
order to be efficient, the immune response
against HIV gp120 has to focus on a
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molecule but not be directed to neighbor-
ing epitopes.
Structural studies have shown that most
of the antibodies that are able to neutralize
HIV harbor atypical properties. Thus, the
broadly neutralizing antibody 2G12 is able
to swap its heavy chains in order to form
an extended binding surface consisting of
three binding sites, an efficient strategy for
binding to carbohydrate moieties [12].
Other neutralizing antibodies were shown
to possess unusually long and protruding
heavy chain CDR3 [13], sulfated tyrosines
[14], secondary structural motives in the
CDRs [15], additional disulfide bridges,
and/or N-linked glycosylation in the
variable domains [11]. The most common
feature of HIV-neutralizing antibodies,
however, is the large number of somatic
mutations in their variable domains [11].
The presence of these numerous muta-
tions and the use of atypical protein
modifications for efficient HIV neutraliza-
tion suggests that the immune system is
pushed to the limits of the diversity that it
may generate by the mere introduction of
variations in the polypeptide sequence,
and that it explores alternative strategies to
optimize antigenic neutralization. Interest-
ingly, and notwithstanding the recent
characterization of ‘‘extremely’’ broadly
neutralizing antibodies, none of the de-
scribed antibodies was shown to be able to
neutralize all genetic variants of HIV
[1,10]. We propose that this is due to the
exquisite specificity of these antibodies:
minor variations in the target antigenic
determinant of very specific antibodies,
which are inherent to the elevated muta-
bility of HIV, will be hardly accommodat-
ed by the antibodies. In other words, the
tremendous energy the immune system
spends in producing exquisitely specific
and efficient neutralizing antibodies to
HIV occurs at the cost of its capacity to
adapt to the subsequent virus variants to
be generated in the course of infection.
Neutralization of HIV by
Polyreactive Antibodies
In contrast to the report by Zhou et al.
[11], which indicates that absolute epitope
specificity is a necessity for the efficient
neutralization of HIV, the study by
Mouquet and colleagues [16] highlights
the important role of polyreactive anti-
bodies in controlling HIV infection. Poly-
reactivity is defined as the ability of an
antibody molecule to bind several struc-
turally unrelated antigens [17,18]. In
healthy individuals, at least 20% of
circulating immunoglobulins are polyreac-
tive. Polyreactive antibodies have been
proposed as a first line of defense against
pathogens [19]. Indeed, natural polyreac-
tive antibodies have been demonstrated to
synergize with the complement system in
the opsonization of viruses and bacteria,
thus directing the pathogens to secondary
lymphoid organs and facilitating initiation
of adaptive immune responses [20,21].
Mouquet et al. [16] demonstrate that most
of the anti-gp120 antibodies isolated from
patients with high HIV-neutralizing titers
are polyreactive. Interestingly, polyreac-
tive antibodies in patients with HIV are
also highly mutated, as opposed to most
polyreactive antibodies in healthy individ-
uals, which are in a germline configura-
tion, thus suggesting a positive selection of
B cell clones producing polyreactive anti-
bodies with specificity for gp120. The
authors propose that polyreactivity is
utilized as a mechanism to increase the
functional affinity (avidity) of the antibod-
ies for the viral spikes. Thus, the simulta-
neous engagement (heteroligation) of
gp140 (by one arm of an IgG) and of
another yet unidentified structure on the
viral membrane (by the other arm of the
IgG) results in a great improvement in
binding avidity [16]. Thus, this study
confirmed the significance of antibody
avidity in HIV neutralization that had
been predicted earlier by Klein and
Bjorkman [22]. This type of binding is
especially advantageous in the case of
HIV, as viral spikes are sparsely distribut-
ed on the viral membrane, and hardly
neutralized by classical homo-ligation with
monoreactive antibodies [22].
Previous studies have suggested that
polyreactivity might improve the neutrali-
zation capacity of HIV-binding antibodies.
Thus, antibodies 2F5 and 4E10, which are
specific for MPER on gp41, were demon-
strated to be polyreactive and also to
recognize other proteins, i.e., histones,
centromere B, Ro, and phospholipids
[23]. These antibodies were shown to
neutralize HIV by the simultaneous en-
gagement of the membrane and gp41 [24].
Interestingly, the sole interaction with gp41
was not efficient for viral neutralization.
Another polyreactive antibody with HIV-
neutralizing properties is antibody 21c,
which binds to the CD4-induced site on
gp120 [25]. Efficient neutralization of the
virus by 21c was, however, only possible
following the simultaneous engagement of
gp120 and CD4 [25].
The efficient neutralization of HIV by
polyreactive antibodies may appear unex-
pected, given the fact that polyreactive
antibodies are often considered to possess
lower binding affinity than monoreactive
antibodies [17], owing to the entropy
penalty that arises from increased molec-
ular flexibility of the polyreactive para-
topes [26,27]. In many cases of antibody–
antigen interactions, however, unfavorable
changes in entropy have been shown to be
compensated by favorable changes in
enthalpy of binding; the overall binding
affinity is thus generally not considerably
affected [28–32]. Importantly, affinity
alone does not dictate the specificity and
the function of antibodies, which is also
largely determined by the biological con-
text of the interaction [33].
In addition, a polyclonal response
compensates for the possible vulnerability
of individual polyreactive antibodies to
statistical restrictions of their capacity to
bind to highly flexible gp120.
The Molecular Adaptability of
Polyreactive Antibodies Can
Contribute to HIV
Neutralization
Taken together, the aforementioned
studies on polyreactive HIV-neutralizing
antibodies demonstrate the advantage of
polyreactivity mostly as a way to gain in
antigen-binding avidity. We further hy-
pothesize that, in addition to a beneficial
gain in avidity, polyreactive antibodies
may better tolerate the elevated mutabil-
ity of HIV. Many structural and biophys-
ical studies have revealed that polyreac-
tive antibodies, in contrast to highly
specific antibodies, possess flexible and
highly adaptable antigen-binding sites
[26,34–37]. Such high molecular dynam-
ics of the antigen-binding sites of poly-
reactive antibodies creates an extended
ensemble of conformations, with the
capacity to adapt to structurally different
epitopes. Such antibodies would thus
accommodate much more easily structur-
al and/or sequence alterations in prompt-
ly mutating proteins. In contrast, highly
specific antibodies possess rigid and pre-
optimized binding sites to interact with
high specificity to given epitopes [37,38];
small variations in the epitopes would be
sufficient to abrogate the interaction of
even very broadly and potently neutraliz-
ing antibodies. Indeed, biophysical and
structural analysis of the interaction of
antibodies with hen egg lysozyme, used as
a model antigen, have revealed that
polyreactive (less specific) antibodies are
more tolerant to variations in their
epitopes than highly specific antibodies
[39–41].
Most of the surface of gp120 that is
accessible to antibodies is covered with
glycans. Hence, polyreactive antibodies
PLoS Pathogens | www.plospathogens.org 2 June 2011 | Volume 7 | Issue 6 | e1002095that bind carbohydrates may also be of
interest for virus neutralization. However,
2G12, a broadly neutralizing oligoman-
nose-specific antibody proved to be less
tolerant to variations in the glycosylation
pattern of gp120 than the lectin conca-
navalin A [42]. Interestingly, plant lectins
demonstrate intrinsic carbohydrate-bind-
ing polyreactivity, resulting in a better
adaptation to different gp120 glycoforms
[42,43]. This suggests that lectin-like
polyreactive antibodies may be a strategy
towards targeting the diverse glycoforms of
gp120 [43].
While all current HIV vaccination
strategies, based on a structure-assisted
rational vaccine design, aim at eliciting
highly specific antibodies against sites that
are vulnerable to neutralization, we sug-
gest that perennial approaches to combat
promiscuous mutable viruses such as HIV
should also exploit the potential of pro-
miscuous adaptive antibodies. To this end,
vaccine strategies that elicit both highly
specific antibodies and promiscuous HIV-
specific antibodies, while limiting IgG-
dependent transmission of HIV from
dendritic cells to T cells in trans [44],
should be explored.
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